Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review

• Published in: Molecular diagnosis & therapy 2021-11, Vol.25 (6), p.715-734
• Main Authors: Koilakou, Stavroula, Petrou, Panagiotis
• Format: Article
• Language: English
• Subjects: Bevacizumab; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Cancer therapies; Chemotherapy; Clinical trials; Colorectal cancer; Colorectal carcinoma; Cost analysis; Cytotoxicity; Economic analysis; Epidermal growth factor; Epidermal growth factor receptors; Evaluation; Growth factors; Health care; Human Genetics; Laboratory Medicine; Literature reviews; Maintenance; Metastases; Metastasis; Molecular Medicine; Monoclonal antibodies; Morbidity; Mortality; Mutation; Patients; Pharmacotherapy; Subgroups; Sustainability; Systematic Review; Technology assessment; Tumors; Vascular endothelial growth factor
• ISSN: 1177-1062; 1179-2000
• DOI: 10.1007/s40291-021-00560-4

Introduction Colorectal cancer (CRC) is one of the major causes of mortality and morbidity worldwide. The median overall survival (OS) of patients with metastatic CRC (mCRC) has doubled over the last 20 years partly due to the introduction of advanced biologic therapies. However, these treatment modalities bear significant costs on healthcare systems globally, and may jeopardize their fiscal sustainability. The aim of this systematic review was to critically appraise the economic evaluations of monoclonal antibodies in mCRC. Methodology A literature search was performed in the electronic databases of: Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, EMBASE, EMBASE Alert, PUBMED, NHS Economic Evaluation and Health Technology Assessment Database for full articles published from 1 January 2013 to 31 December 2020. Results Twenty economic analyses were identified in the literature that fulfilled the inclusion criteria and evaluated the cost-effectiveness of (a) bevacizumab as first-line treatment for mCRC and as maintenance treatment, (b) cetuximab as first-line treatment, (c) panitumumab versus bevacizumab and cetuximab versus bevacizumab as first-line treatment, (d) aflibercept and ramucirumab as second-line treatment, (e) cetuximab and panitumumab as third-line treatment, (f) cetuximab versus panitumumab as later lines of treatment, and (g) RAS testing prior to anti-epidermal growth factor receptor (EGFR) treatment. Conclusions Bevacizumab in combination with chemotherapy is cost-effective as neither first-line treatment nor maintenance treatment. Sequential treatment with bevacizumab in first-line and second-line treatment was also not cost-effective. Testing for KRAS and extended RAS mutations is cost-effective and should be performed prior to anti-EGFR treatment. In the RAS wild-type subgroup of mCRCs the use of anti-EGFR (panitumumab or cetuximab) in first-line treatment leads to a more favorable cost-effectiveness profile than the corresponding anti-VEGF (bevacizumab). Cetuximab is not cost-effective as a first-line treatment. Anti-EGFR administration is not a cost-effective strategy in third-line treatment, even for RAS wild-type mCRCs, compared to best supportive care. Aflibercept was superior to ramucirumab and costed less, but neither were cost-effective compared to standard care.